Skip to Content

Axumin Approval History

FDA Approved: Yes (First approved May 27, 2016)
Brand name: Axumin
Generic name: fluciclovine F 18
Dosage form: Injection
Company: Blue Earth Diagnostics, Ltd.
Treatment for: Diagnosis and Investigation

Axumin (fluciclovine F 18) a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected recurrent prostate cancer.

Development History and FDA Approval Process for Axumin

May 27, 2016Approval FDA Approves Axumin (fluciclovine F 18) Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.